This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing current treatment options for CLL and the potential of Nurix Therapeutics' NX-5948, a BTK degrader
Ticker(s): NRIX, ABBV, BGNE, AZN, LLYWho's the expert?
Institution: Mayo
- Hematologist/oncologist and bone marrow transplant physician with a clinical focus on chronic lymphocytic leukemia, lymphoid malignancies, and rare histiocytic neoplasms
- interested in incorporating various modalities of therapy that help serve individual patient needs, including using novel targeted therapies, bispecific T-cell engagers, and cellular therapy.
- part of the bone marrow transplant and chimeric antigen receptor (CAR) T-cell therapy programs where he prescribes specialized treatments for patients with lymphoid malignancies.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
